Peroxynitrite protects RAW 264.7 macrophage from Lipopolysaccharide/Interferon-gamma-induced cell death.
Peroxynitrite, formed by the interaction of superoxide with nitric oxide, has previously been implicated mostly as a cytotoxic agent. In contrast, its physiological and, possibly, beneficial effects are largely unknown. We have previously shown [Journal of Biological Chemistry, 1997, 272, 7253] that RAW 264.7 macrophages can be selected to be resistant toward lipopolysaccharide (LPS)/interferon-gamma (IFN-gamma)-induced cytotoxicity. Resistant cells produced comparable amount of nitric oxide, but showed increased formation of superoxide, which might lead to increased production of peroxynitrite. We utilized this well characterized cell model to seek evidence that peroxynitrite might cause protection of RAW cells from cytokine toxicity. Exogenous peroxynitrite (30-50 microM), applied to RAW cells before cytokine stimulation, dramatically reduced LPS/IFN-gamma toxicity. Measurement of cell viability after overnight incubation with a mixture of LPS (10 microg/ml) and IFN-gamma (100 U/ml), showed that pretreatment with 40 microM peroxynitrite completely reverted LPS/IFN-gamma cytotoxicity. Differently, pretreatment of RAW cells with peroxynitrite (10-60 microM) did not prevent cytotoxicity induced by the nitric oxide-donors S-Nitroso-L-glutathione (0.2-1 mM), or spermine NONOate (0.2-2 mM), and by Actimomycin D (0.5-1 microg/ml), suggesting that the protective effect is specific for the LPS/IFN-gamma pathway. These results were confirmed through extensive controlled studies aimed to optimize cell exposure to peroxynitrite, and showed that peroxynitrite protects macrophages from cytokine-induced cytotoxicity.
Scivittaro
V
V
Molecular Cardiovascular Research Center, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, Ohio 44106, USA.
Boggs
S
S
Mohr
S
S
Lapetina
E G
EG
D000818:Animals; D016923:Cell Death / Q000187:drug effects*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects*; D003609:Dactinomycin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005978:Glutathione / Q000031:analogs & derivatives / Q000494:pharmacology; D007371:Interferon-gamma / Q000633:toxicity*; D008070:Lipopolysaccharides / Q000633:toxicity*; D008264:Macrophages / Q000166:cytology / Q000187:drug effects*; D051379:Mice; D009566:Nitrates / Q000494:pharmacology*; D009569:Nitric Oxide / Q000633:toxicity; D009589:Nitrogen Oxides; D009603:Nitroso Compounds / Q000494:pharmacology; D026422:S-Nitrosoglutathione; D013096:Spermine / Q000031:analogs & derivatives / Q000494:pharmacology
D008070:Lipopolysaccharides; D009566:Nitrates; D009589:Nitrogen Oxides; D009603:Nitroso Compounds; C091861:spermine nitric oxide complex; D003609:Dactinomycin; C039642:peroxynitric acid; D013096:Spermine; D009569:Nitric Oxide; D026422:S-Nitrosoglutathione; D007371:Interferon-gamma; D005978:Glutathione